Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,124 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06988956RecruitingPhase 2
Nimotuzumab Plus Chemoradiation for Older Adults with Esophageal Cancer
This trial tests adding nimotuzumab, a targeted therapy, to standard chemoradiation for elderly patients with esophageal squamous cell cancer. It aims to see if the combination improves outcomes.
NanjingAges 75 years+ - NCT07049926RecruitingPhase 1/Phase 2
Combination therapy study for advanced kidney cancer
This trial tests new drug combinations for people with advanced kidney cancer whose disease returned after a prior immunotherapy. It's designed to find better treatment options for those who have not received other treatments for advanced disease.
San Francisco, CaliforniaAges 18–120 - NCT07046832Enrolling by invitation
Augmented reality needle guidance for soft tissue biopsy
This trial tests a new augmented reality system that helps guide the needle during a soft-tissue biopsy. It may make the procedure more accurate and easier for your doctor.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07046923RecruitingPhase 1
A study of LY4175408 for advanced cancer
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
Stanford, CaliforniaAges 18 years+ - NCT07047482Recruiting
p16 marker study in colorectal cancer
This study looks at a marker called p16 in colorectal cancer tissue. It aims to find out if p16 is linked to how the disease behaves, which could help guide treatment decisions.
Sohag, RecruitingAges Any age - NCT07054346RecruitingPhase 1
Radioactive drugs before prostate surgery for high-risk prostate cancer
This trial compares two radioactive drugs (177Lu-PSMA-617 and 225Ac-PSMA-617) given before prostate removal surgery in men with high-risk prostate cancer that has not spread far. The goal is to see which drug is better at shrinking the tumor and reducing the chance of cancer coming back.
San Francisco, CaliforniaAges 18 years+ - NCT07047586RecruitingPhase 2
Lenvatinib plus Tislelizumab vs Lenvatinib alone for liver cancer
This trial tests whether combining two targeted drugs (lenvatinib and tislelizumab) works better than lenvatinib alone for people with advanced liver cancer whose disease worsened after prior treatment with an immunotherapy and a blood vessel growth blocker (bevacizumab).
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07042295RecruitingPhase 2
Amivantamab or Cetuximab for Skin Cancer in People with Weakened Immune Systems
This trial tests two drugs, amivantamab with hyaluronidase or cetuximab, in people with weakened immune systems who have advanced skin cancer (squamous cell carcinoma). The goal is to see if these treatments can help shrink or control the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07038096RecruitingPhase 1/Phase 2
Testing ZG006 and ZG005 for lung and neuroendocrine cancers
This trial tests two new drugs, ZG006 and ZG005, for people with advanced small cell lung cancer or neuroendocrine carcinoma. The goal is to see if these drugs can shrink tumors or slow cancer growth.
Guanzhou, GuangdongAges 18–70 - NCT07036380RecruitingPhase 2
Testing MP0317 with chemotherapy for advanced bile duct cancer
This trial tests if adding a new drug (MP0317) to standard chemoimmunotherapy helps people with advanced bile duct cancer. It's for patients who haven't had treatment yet, except for certain past adjuvant therapy.
BesançonAges 18 years+ - NCT07034053RecruitingPhase 1/Phase 2
Clofarabine for advanced bladder cancer
This trial tests the drug clofarabine in people with advanced bladder cancer that has spread or cannot be removed by surgery. It is for those who have already tried standard treatments or chose not to have them.
ViennaAges 18 years+ - NCT07043972RecruitingPhase 2
Gemcitabine and carboplatin after EV-pembrolizumab for bladder cancer
This trial tests a combination of two chemotherapy drugs, gemcitabine and carboplatin, for people whose bladder cancer has progressed after treatment with enfortumab vedotin plus pembrolizumab. The goal is to see if this chemo regimen can help control the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07039201Recruiting
A cell therapy for liver cancer that has progressed on other treatments
This study tests a new cell therapy (called CG-102-12C) for advanced liver cancer that has a specific marker (GPC3) and has stopped responding to standard treatments. The therapy uses your own immune cells, specially trained to attack the cancer. This might be an option if you have tried other treatments and they no longer work or cause bad side effects.
Hangzhou, ZhejiangAges 18–75 - NCT07039162RecruitingPhase 2
Tislelizumab with chemo and radiation before surgery for advanced esophageal cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
Kaohsiung CityAges 20 years+ - NCT07036874Recruiting
Predicting outcomes in liver cancer with non-invasive tests
This study uses non-invasive tests, like scans or blood tests, to predict how well people with liver cancer (hepatocellular carcinoma, or HCC) will do after curative treatment. It may help doctors better understand your condition without needing invasive procedures.
Hong KongAges 18 years+ - NCT07035626RecruitingPhase 1/Phase 2
Spermidine to prevent dry mouth from radiation therapy
This trial tests whether spermidine (a natural compound) can help prevent dry mouth caused by radiation treatment for head and neck cancer. It is for patients who will receive a significant dose of radiation to their saliva glands.
Chengdu, SichuanAges 18–80 - NCT06277791RecruitingPhase 2
Adebrelimab plus chemo before surgery for advanced oral cancer
This trial is testing a new combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (paclitaxel and carboplatin) given before surgery for advanced oral cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Hubei, WuhanAges 18–75 - NCT07027436RecruitingPhase 3
Immunotherapy plus radiation before liver cancer surgery
This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) plus radiation before surgery works better than radiation alone before surgery for people with resectable liver cancer. It's for those with a single tumor (or a few small nearby spots) that hasn't spread.
Hamilton, OntarioAges 18 years+ - NCT07029256Recruiting
Ultrasound-guided biopsy for bladder cancer staging
This trial uses an ultrasound-guided needle biopsy to check if bladder cancer has spread beyond the bladder. It may help doctors stage the cancer more accurately before surgery.
Rochester, MinnesotaAges 18 years+ - NCT07030569Recruiting
Predicting treatment response in metastatic breast cancer
This trial studies how well CT and PET scans can predict if a certain type of breast cancer will respond to a targeted treatment. It focuses on women who had a biopsy of the liver, lung, or chest lining after the cancer spread.
MilanAges Any age - NCT07033572Recruiting
Hybrid scope surgery and ablation for both sides of thyroid cancer
This study tests a combined approach—removing the main thyroid cancer with a tiny camera (endoscope) and using targeted heat to destroy a small nodule on the opposite side. It aims to treat both sides of the thyroid at once with less scarring and faster recovery.
Fuzhou, FujianAges 18–65 - NCT06995105RecruitingPhase 1/Phase 2
Personalized mRNA Vaccine for Advanced Liver Cancer
This trial tests a personalized mRNA vaccine made from your tumor's unique genetic markers. It is for people with advanced liver cancer who have not yet received any treatment.
Hangzhou, ZhejiangAges 18–75 - NCT07019844Recruiting
PSMA PET scan for liver cancer staging
This trial tests if a special PET scan (PSMA PET) can better stage liver cancer that has not been treated yet and is at a moderate to advanced stage (BCLC B or C). It may help guide treatment decisions.
West Los Angeles, CaliforniaAges 18 years+ - NCT07018037Recruiting
TTV levels during first immunotherapy for kidney cancer
This study looks at whether a virus called TTV (torque teno virus) in the blood can help predict how well immunotherapy works for advanced kidney cancer. If you have clear cell renal cell carcinoma that has spread and are about to start your first immunotherapy, you may be able to join.
Rome, RomeAges 18 years+
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,124 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.